If the company is near to potential revenue with a

If the company is near to potential revenue with a definitive Phase 3 trial in action (B-ABSSSI in this case), it's probably not a bad idea to do the R/S. But first, they really need to get the SPA, then I supposed everything will fall into place later on, I don't know what exactly is Leo's strategy here. Cynapsus did something similar and their stock price is relatively stable with a lot of institutional investors holding the shares now. Don't compare to AVXL because it's just a Phase 1 company.